Hudson Bay Capital Management
IBER

Hudson Bay Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Hudson Bay Capital Management’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-716,613
Closed -$7.23M – 1177
2022
Q4 		$7.23M Hold
716,613
– – 0.07% 245
2022
Q3 		$7.1M Buy
716,613
+99,612
+16% +$982K 0.06% 262
2022
Q2 		$6.05M Hold
617,001
– – 0.05% 347
2022
Q1 		$6.05M Hold
617,001
– – 0.08% 291
2021
Q4 		$6M Hold
617,001
– – 0.06% 281
2021
Q3 		$5.98M Sell
617,001
-4,749
-0.8% -$45.9K 0.08% 273
2021
Q2 		$6.01M Buy
+621,750
New +$6.05M 0.07% 279

Hudson Bay Capital Management's IBER Position: Q1 2023 in Review

Hudson Bay Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 716,613 shares — an estimated $7.23M sold.

Hudson Bay Capital Management first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $7.23M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

  • Hudson Bay Capital Management reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Hudson Bay Capital Management sold 716,613 Ibere Pharmaceuticals shares in Q1 2023, an estimated $7.23M.
  • Hudson Bay Capital Management first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Hudson Bay Capital Management's Ibere Pharmaceuticals position peaked at $7.23M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Hudson Bay Capital Management's 13F filing for Q1 2023, filed 15 May 2023.